| Literature DB >> 33718249 |
Yan Zhao1, Yanting Zhu1, Haiqing Wang1, Chao Ji1.
Abstract
Few studies have evaluated acitretin as a primary treatment for cutaneous squamous cell carcinoma (CSCC). We report, for the first time, three cases of CSCC successfully treated with acitretin and clarithromycin. A literature review on this subject was also was performed. This case report included three patients with CSCC treated with acitretin and clarithromycin at the First Affiliated Hospital of Fujian Medical University (2008-2019). Patient 1 (83-year-old woman, ulcerated mass on the left cheek), patient 2 (97-year-old woman, painful mass on the left cheek) and patient 3 (76-year-old woman, large mass on the right ankle) received 8, 6, and 30 courses of combination therapy. All patients tolerated the adverse effects (pseudotumor cerebri and mucocutaneous dryness) and achieved complete regression within 6 months. Patients 1, 2, and 3 have not experienced recurrence during a 10-, 3-, and 6-year follow-up. Acitretin has limited efficacy as a monotherapy for CSCC. Our experience indicates that combination therapy with acitretin and clarithromycin may be an effective and well-tolerated treatment for unresectable CSCC.Entities:
Keywords: acitretin; clarithromycin; combination therapy; complete regression; cutaneous squamous cell carcinoma
Year: 2021 PMID: 33718249 PMCID: PMC7952297 DOI: 10.3389/fonc.2021.650974
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244